A detailed history of Wellington Management Group LLP transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Wellington Management Group LLP holds 3,922,058 shares of XENE stock, worth $153 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
3,922,058
Holding current value
$153 Million
% of portfolio
0.03%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$42.66 - $50.04 $167 Million - $196 Million
3,922,058 New
3,922,058 $169 Million
Q4 2023

Feb 12, 2024

BUY
$28.7 - $46.46 $119 Million - $193 Million
4,162,654 New
4,162,654 $192 Million
Q3 2023

Nov 14, 2023

BUY
$34.16 - $39.73 $23.1 Million - $26.9 Million
677,057 Added 64.42%
1,728,108 $59 Million
Q2 2023

Aug 14, 2023

BUY
$34.84 - $43.54 $28 Million - $35 Million
803,614 Added 324.78%
1,051,051 $40.5 Million
Q1 2023

May 12, 2023

BUY
$33.46 - $40.35 $8.28 Million - $9.98 Million
247,437 New
247,437 $8.86 Million

Others Institutions Holding XENE

About Xenon Pharmaceuticals Inc.


  • Ticker XENE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,263,500
  • Market Cap $2.43B
  • Description
  • Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...
More about XENE
Track This Portfolio

Track Wellington Management Group LLP Portfolio

Follow Wellington Management Group LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wellington Management Group LLP, based on Form 13F filings with the SEC.

News

Stay updated on Wellington Management Group LLP with notifications on news.